Sanofi Co-Leads $787M Round for AI Drug Discovery, Licenses Kali Therapeutics’ Candidate
Sanofi co-led Earendil Labs’ $787M Series A financing with Dimension Capital and Pfizer & Hillhouse’s fund, boosting its AI-powered drug discovery platform and funding over 40 programs including HXN-1001’s move into Phase II for IBD. In a deal, Sanofi licensed Kali Therapeutics’ experimental autoimmune candidate to bolster its inflammation pipeline.
1. Sanofi Joins $787M Financing Round
Sanofi led a $787 million Series A funding for Earendil Labs alongside Dimension Capital and the Pfizer & Hillhouse Biotech Development Fund. The capital will expand Earendil’s AI-driven discovery platform, hire additional scientists and engineers, and support over 40 therapeutic programs.
2. HXN-1001 Advances to Phase II Trials
Earendil’s leading candidate, HXN-1001, is a half-life extended TL1A therapy set to enter Phase II trials for Crohn’s disease and ulcerative colitis. The first-in-human Phase I safety study was completed in July 2025, positioning HXN-1001 for midstage efficacy evaluation.
3. Sanofi Licenses Kali Therapeutics’ Autoimmune Candidate
In a separate agreement, Sanofi acquired rights to develop and commercialize a private autoimmune therapy from Kali Therapeutics. The deal broadens Sanofi’s inflammatory disease portfolio by adding an early-stage candidate targeting multiple autoimmune indications.